In conclusion, our study showed that patients with EGFR-mutated NSCLC and higher PD-L1 expression received a greater benefit of treatment with PD-1 inhibitors in terms of ORR and PFS than patients with low PD-L1 expression did. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.